Results 151 to 160 of about 757,323 (338)

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Malignant Melanoma of Nose and Paranasal Sinuses: 2 Case Reports [PDF]

, 2010
Malignant melanoma is one of the rare and highly aggressive diseases of the sinonasal cavity. High index of suspicion is required for diagnosis as the patient usually presents with non specific signs and symptoms.
Gupta, N, Sanjeev Bhagat, Varshney, S, Singh, R, Saurabh Varshney, Rakesh Singh, Bhagat, S, Bist, SS, Sampan Singh Bist, Nitin Gupta   +9 more
core  

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan, Pooja Patel, Jeva Cernova, Sarah Hogan, Jason Thomson, Efthymios Hadjimichael, Sharanpal Jeetle, Dorota Markiewicz, Michael Sheaff, Nilukshi Wijesuriya, Mark Hawthorne, Graeme Moir, Matthew Stodell, Kapil Bhargava, Suchitra Chinthapalli, Catherine A. Harwood   +15 more
wiley   +1 more source

Cutaneous Malignant Melanoma in a Cat [PDF]

, 2009
Melanomas are neoplasia of melanocytes and melanoblasts which may in benign or malign character. Malign melanoma is typically considered as a rare neoplasm in cats.
Karakurum, Mehmet Cagri, Pekcan, Zeynep, Ozmen, Ozlem   +2 more
core  

Demographic and clinical features of cutaneous malignant melanoma patients: A single center cohort study. [PDF]

North Clin Istanb, 2023
Semiz Y, Aktas E, Topal IO.
europepmc   +1 more source

Malignant cutaneous melanoma: A review

Journal of British Surgery, 1953
R B, WRIGHT, D H, CLARK, J A, MILNE
openaire   +2 more sources

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Anti‐PD‐1 response has been associated with higher PD‐1 ligand (PD‐L1) expression levels in different cancer types. Cemiplimab, an anti‐PD‐1 antibody, has been shown to induce a response rate of 31% and 22% in patients with locally advanced basal cell carcinoma (BCC) and metastatic BCC respectively, who have progressed or are ...
Isabella Dommann, Gaetana Restivo, Isabel Kolm, Federica Sella, Patrick Turko, Phil F. Cheng, Mitchell Levesque, Corina Dommann‐Scherrer, Reinhard Dummer, Egle Ramelyte   +9 more
wiley   +1 more source